Sonoma Pharmaceuticals, Inc. — Director's Dealing 2012

Aug 27, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oculus Innovative Sciences, Inc. (OCLS)
CIK: 0001367083
Period of Report: 2012-08-24

Reporting Person: Schutz James J (Director, Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-08-24	Stock Option (Right to Buy)	$0.93	A	150000	Acquired	2022-08-24	Common Stock (150000)	Direct

Footnotes

F1: The option will vest 1/36th per month over a three year vesting schedule commencing on the date of grant.

F2: The option grant was made pursuant to the Issuer's 2012 Bonus Plan in lieu of cash.